> In the first half of this year, Danish GDP rose at a 1.7 percent annualized rate thanks to the contribution of Novo Nordisk, the drug maker responsible for an

> In the first half of this year, Danish GDP rose at a 1.7 percent annualized rate thanks to the contribution of Novo Nordisk, the drug maker responsible for anti-obesity blockbusters Ozempic and Wegovy. Without soaring production and profits at Novo Nordisk, Danish GDP would have shrunk by 0.3 percent. Incredible. While people are sharing anecdotes, I’ll add mine. My wife went on Wegovy in January — she’s lost over 50 pounds. (Having four kids really does a number on you.) She’s sick less often, she’s stopped complaining about her knees hurting, she’s more active. She looks like a different person! All around, a huge win. I really pray there’s no long-term side-effects lurking for everybody who’s benefiting from these drugs.